SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
95
|
RAISING THE WALL IN MATERNAL/FETAL IMMUNITY (ABSTRACT
67)
Sallie Permar
Duke Human Vaccine Institute, Durham, NC, USA
HUGGING PHYLOGENETIC TREES: USE OF MOLECULAR ANALYSIS FOR PUBLIC HEALTH INTERVENTION (ABSTRACT
68)
Alexandra M. Oster
CDC, Atlanta, GA, USA
FALL IN HCV INCIDENCE IN HIV+ MSM IN LONDON FOLLOWING WIDER ACCESS TO DAA THERAPY (ABSTRACT
85)
Lucy Jane Garvey
Imperial College Healthcare NHS Trust, London, United Kingdom
HCV REINFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY (ABSTRACT
86)
Daniel S. Fierer
Icahn School of Medicine at Mount Sinai, New York, NY, USA
A PHASE 1 STUDY OF LEDIPASVIR/SOFOSBUVIR IN PREGNANT WOMEN WITH HEPATITIS C VIRUS (ABSTRACT
87)
Catherine Anne Chappell
Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA
INCIDENT DIABETES AND GLUCOSE CONTROL AFTER HCV TREATMENT WITH DAAS IN ERCHIVES (ABSTRACT
88)
Adeel Ajwad Butt
Weill Cornell Medical College, New York, NY, USA
INTRAHEPATIC HEPATITIS C KINETICS WITH DIRECT-ACTING ANTIVIRALS IN HIV COINFECTION (ABSTRACT
89)
Ashwin Balagopal
Johns Hopkins University, Baltimore, MD, USA
HIV VIREMIA AND LOW CD4+ INCREASE HCC RISK IN THOSE WITHOUT ADVANCED LIVER FIBROSIS (ABSTRACT
90)
Jessie Torgersen
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
SINGLE HEPATOCYTE ANALYSIS IN HIV-HBV COINFECTION SHOWS HBV TRANSCRIPTION SILENCING (ABSTRACT
91)
Chloe Thio
Johns Hopkins University School of Medicine, Baltimore, MD, USA
PROTECTION AGAINST PENILE OR INTRAVENOUS SHIV CHALLENGES BY BNAB 10-1074 OR 3BNC117 (ABSTRACT
100)
David A Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
PROTECTION AGAINST VAGINAL SHIV INFECTION WITH AN INSERT CONTAINING TAF AND EVG (ABSTRACT
101)
Charles Dobard
CDC, Atlanta, GA, USA
MODERATE EFFICACY OF ORAL SINGLE-AGENT TAF AGAINST VAGINAL SHIV INFECTION IN MACAQUES (ABSTRACT
102)
Ivana Massud
Centres for Disease Control and Prevention, Atlanta, GA, USA
LYMPHOID TISSUE PHARMACOKINETICS OF TENOFOVIR-ALAFENAMIDE VS -DISOPROXIL FUMARATE (ABSTRACT
103)
Courtney V. Fletcher
University of Nebraska Medical Center, Omaha, NE, USA
THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS (ABSTRACT
104)
Charles B Hare
Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA
USING EHR DATA TO IDENTIFY POTENTIAL PREP CANDIDATES IN A LARGE HEALTH CARE SYSTEM (ABSTRACT
105)
Julia L. Marcus
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
PERSISTENCE WITH HIV PREEXPOSURE PROPHYLAXIS IN THE UNITED STATES, 2012-2016 (ABSTRACT
106)
Ya-Lin A Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
IMPACT OF PREP ON DRUG RESISTANCE AND ACUTE HIV INFECTION, NEW YORK CITY, 2015-2017 (ABSTRACT
107)
Kavita Misra
New York City Department of Health and Mental Hygiene, Long Island City, NY, USA
IPT AND PREGNANCY OUTCOMES IN HIV-POSITIVE WOMEN: THE TSHEPISO COHORT (ABSTRACT
77)
Nicole Salazar-Austin
Johns Hopkins University School of Medicine, Baltimore, MD, USA
POTENTIAL CONCERN FOR TIMING OF DMPA INJECTION AMONG WOMEN TREATED FOR HIV AND TB (ABSTRACT
78)
Rosie Mngqibisa
Enhancing Care Initiative, Durban RSA, South Africa
IMPROVING CHILD TUBERCULOSIS CONTACT MANAGEMENT IN LESOTHO (ABSTRACT
79)
Yael Hirsch-Moverman
Columbia University, Mailman School of Public Health, New York, NY, USA
SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR (ABSTRACT
80)
Kelly E Dooley
Johns Hopkins University, Baltimore, MD, USA
PHARMACOKINETICS AND SAFETY OF ADJUSTED DARUNAVIR/RITONAVIR WITH RIFAMPIN IN PLWH (ABSTRACT
81)
Gary Maartens
University of Cape Town, Cape Town, South Africa
EARLY BACTERICIDAL ACTIVITY OF HIGH-DOSE ISONIAZID AGAINST MULTIDRUG-RESISTANT TB (ABSTRACT
82)
Kelly E Dooley
Johns Hopkins University, Baltimore, MD, USA
LONG-TERM MORTALITY AFTER TUBERCULOSIS CURE IN THE CIPRA HT-001 TRIAL (ABSTRACT
83)
Yvetot Joseph
Les Centres GHESKIO, Haiti, Port-au-Prince, Haiti
QT EFFECTS OF BEDAQUILINE, DELAMANID OR BOTH IN MDR-TB PATIENTS: THE DELIBERATE TRIAL (ABSTRACT
84)
Gary Maartens
University of Cape Town, Cape Town, South Africa
IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071(POPART) (ABSTRACT
92)
Richard J Hayes
London School of Hygiene and Tropical Medicine, London, United Kingdom
A RANDOMIZED TRIAL ON INDEX HIV SELF-TESTING FOR PARTNERS OF ART CLIENTS IN MALAWI (ABSTRACT
93)
Kathryn Dovel
University of California Los Angeles, Westwood, CA, USA
VIRAL LOAD SUPPRESSION AND YIELD OF HIV TESTS ARE SPATIALLY CORRELATED, KENYA 2015-17 (ABSTRACT
94)
Anthony Waruru
U.S. Centers for Disease Control and Prevention, Nairobi, Kenya
HIV TESTING, TREATMENT, AND VIRAL SUPPRESSION COVERAGE IN A CLUSTER-RANDOMIZED TRIAL (ABSTRACT
95)
Kathleen Wirth
Harvard T.H. Chan School of Public Health, Boston, MA, USA
FACTORS ASSOCIATED WITH PERSISTENT VIREMIA WITH UNIVERSAL “TEST & TREAT” IN UGANDA (ABSTRACT
96)
Eshan Uday Patel
Johns Hopkins University, Baltimore, MD, USA
VIROLOGIC FAILURE, LOW-LEVEL VIREMIA, AND VIRAL BLIP AFTER HIV RNA SUPPRESSION (ABSTRACT
97)
Jennifer S Lee
Johns Hopkins University, Baltimore, MD, USA
FIFTY-PERCENT REDUCTION IN HIV INCIDENCE IN CHOKWE DISTRICT, MOZAMBIQUE, 2014-2017 (ABSTRACT
98)
Duncan Alan MacKellar
CDC, Lilburn, GA, USA
A MODEL IMPACT ANALYSIS OF PREP AND TASP IN FSW DEMONSTRATION PROJECT IN BENIN (ABSTRACT
99)
Lily Geidelberg
Imperial College London, London, UT, United Kingdom
ORAL ABSTRACT MODERATOR
Stefan Sarafianos
Emory University School of Medicine, Atlanta, GA, USA
A VIRUS-PACKAGEABLE CRISPR SCREEN IDENTIFIES HIV RESTRICTION AND DEPENDENCY FACTORS (ABSTRACT
69)
Molly Ohainle
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
A FUNCTIONAL MAP OF HIV-HOST INTERACTIONS IN PRIMARY HUMAN CD4+ T CELLS (ABSTRACT
70)
Judd F Hultquist
Northwestern University, Chicago, IL, USA
HIV-1 COMPLEXES TRAFFIC WITH HOST CPSF6 ON MICROTUBULES PRIOR TO NUCLEAR ENTRY (ABSTRACT
71)
Zandrea Ambrose
University of Pittsburgh, Pittsburgh, PA, USA
HIV-1 CAPSID DETERMINANTS THAT INFLUENCE NUCLEAR ENVELOPE DOCKING AND NUCLEAR IMPORT (ABSTRACT
72)
Mohamed Husen Munshi
National Cancer Institute, Frederick, MD, USA
SINGLE HIV-1 VIRUS IMAGING WITH CA-EGFP QUESTIONS A ROLE OF NUCLEAR CA IN INTEGRATION (ABSTRACT
73)
Frauke Christ
Katholieke University Leuven, Leuven, Belgium
DISRUPTION OF HIV-1 LTR SEQUENCE BY A NUCLEOCAPSID MUTATION LEADS TO DTG RESISTANCE (ABSTRACT
74)
Atsuko Hachiya
National Hospital Organization Nagoya Medical Center, Aichi, Japan
INTEGRASE (IN) TETRAMERS ARE THE AUTHENTIC TARGETS FOR ALLOSTERIC HIV-1 IN INHIBITORS (ABSTRACT
75)
Pratibha Chowdary Koneru
University of Colorado, Aurora, CO, USA
TARGETING VIRUS ENV AND CD44 IMPROVES BBAB AVIDITY AND NEUTRALIZATION POTENCY (ABSTRACT
76)
Djin-Ye Oh
Aaron Diamond AIDS Research Center, New York, NY, USA
THEMED DISCUSSION LEADER
Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
ENTRY KINETICS OF GLOBALLY REPRESENTATIVE AND VERTICALLY TRANSMITTED HIV ENVELOPES (ABSTRACT
166)
Nicholas E. Webb
University of California Los Angeles, Los Angeles, CA, USA
CD4-DEPENDENT MODULATION OF HIV-1 ENTRY BY LY6E (ABSTRACT
167)
Shan-Lu Liu
The Ohio State University, Columbus, OH, USA
ELUCIDATING MECHANISMS BY WHICH MUTATIONS IN ENV CONTRIBUTE TO HIV-1 DRUG RESISTANCE (ABSTRACT
168)
Rachel Van Duyne
National Cancer Institute, Frederick, MD, USA
NONRANDOM GENERATION OF DELETIONS WITHIN HIV PROVIRAL SEQUENCES IN VIVO (ABSTRACT
169)
Bonnie Hiener
The Westmead Institute for Medical Research, Westmead, Australia
HOST FACTORS INFLUENCE SIV AND HIV-1 INFECTION AND SENSITIVITY TO CAPSID INHIBITORS (ABSTRACT
170)
Carsten Münk
Heinrich-Heine-University Hospital, Düsseldorf, Germany
THEMED DISCUSSION LEADER
John Frater
University of Oxford, Oxford, United Kingdom
|
<< first | < prev
page:
of 2
|
records per page:
next >
| last >>
|
| pages: 1 2
|
presentations:
1 to
50 of
95
|
